Evidence map›Paper›PMID 35000597›Full record

ArticleJournal of hematology & oncology2022

Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia.

Helen Parry, Graham McIlroy, Rachel Bruton, Sarah Damery, Grace Tyson, Nicola Logan, Chris Davis, Brian Willett, Jianmin Zuo, Myah Ali and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 9 institutions in 1 country.

Helen ParryInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.ORCID 0000-0002-9707-8167
Graham McIlroyInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Rachel BrutonInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
Sarah DameryInstitute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.
Grace TysonMRC- University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK.
Nicola Logan
Chris DavisMRC- University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK.
Brian WillettMRC- University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK.
Jianmin ZuoInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
Myah AliInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
Manjit KaurInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
Christine StephensInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
Dawn BrantInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
Ashley OtterUK Health Security Agency, Porton Down, Salisbury, SP4 OJG, UK.
Tina McSkeaneCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT, UK.
Hayley RolfeCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT, UK.
Sian FaustiniInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
Alex RichterInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
Sophie LeeDepartment of Haematology, The Royal Wolverhampton NHS Trust. Wolverhampton Hospital, Wolverhampton, WV10 0QP, UK.
Farooq WandrooDepartment of Haematology. Sandwell and West Birmingham, NHS Trust, Birmingham, B18 7QH, UK.
Salim ShafeekDepartment of Haematology, Worcestershire Acute Hospitals NHS Trust, Worcester, WR5 1DD, UK.
Guy PrattQueen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, B15 2TH, UK.
Shankara PaneeshaBirmingham Heartlands Hospital, University Hospitals Birmingham, Birmingham, B9 5SS, UK.
Paul MossInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK. p.moss@bham.ac.uk.
University of Birmingham · GBMRC University of Glasgow Centre for Virus Research · GBCancer Research UK Clinical Trials Unit · GBHeartlands Hospital · GBQueen Elizabeth Hospital Birmingham · GBSandwell & West Birmingham Hospitals NHS Trust · GBThe Royal Wolverhampton NHS Trust · GBUK Health Security Agency · GBWorcestershire Acute Hospitals NHS Trust · GB

Funding

Medical Research Council MC_PC_19026Medical Research Council MC_PC_20031Medical Research Council MC_PC_20060Medical Research Council MR/V028448/1
6 · The paper itself

Abstract

backgroundImmune suppression is a clinical feature of chronic lymphocytic leukaemia (CLL), and patients show increased vulnerability to SARS-CoV-2 infection and suboptimal antibody responses.

methodWe studied antibody responses in 500 patients following dual COVID-19 vaccination to assess the magnitude, correlates of response, stability and functional activity of the spike-specific antibody response with two different vaccine platforms.

resultsSpike-specific seroconversion post-vaccine was seen in 67% of patients compared to 100% of age-matched controls. Amongst responders, titres were 3.7 times lower than the control group. Antibody responses showed a 33% fall over the next 4 months. The use of an mRNA (n = 204) or adenovirus-based (n = 296) vaccine platform did not impact on antibody response. Male gender, BTKi therapy, prophylactic antibiotics use and low serum IgA/IgM were predictive of failure to respond. Antibody responses after CD20-targeted immunotherapy recovered 12 months post treatment. Post-vaccine sera from CLL patients with Spike-specific antibody response showed markedly reduced neutralisation of the SARS-CoV-2 delta variant compared to healthy controls. Patients with previous natural SARS-CoV-2 infection showed equivalent antibody levels and function as healthy donors after vaccination.

conclusionsThese findings demonstrate impaired antibody responses following dual COVID-19 vaccination in patients with CLL and further define patient risk groups. Furthermore, humoural protection against the globally dominant delta variant is markedly impaired in CLL patients and indicates the need for further optimisation of immune protection in this patient cohort.

Indexed as

AdultAgedAged, 80 and overAntibodies, NeutralizingAntibody FormationCOVID-19COVID-19 VaccinesFemaleHEK293 CellsHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedSARS-CoV-2Antibodies, NeutralizingCOVID-19 VaccinesAntibodyCLLCOVIDLeukaemiaSARS-CoV-2Vaccination

Identifiers

PMID35000597
PMCPMC8743056
OpenAlexW4220734622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.